Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Sep 29 · above the Ichimoku cloud · RSI 59 · MACD below its signal
None of the 29 investors followed here reported a position in ONT.L in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ONT.L trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Ip2ipo Ltd | — | 10.00M | — |
| Sep 30, 2026 | Ip2ipo Ltd | — | 6.66M | — |
| Sep 13, 2026 | Keher (Nick) | Bought at price 2.12 per share. | 96 | $203 |
| Sep 13, 2026 | Keher (Nick) | — | 96 | — |
| Sep 13, 2026 | Parys (Francis Van) | Bought at price 2.12 per share. | 96 | $203 |
| Sep 13, 2026 | Parys (Francis Van) | — | 96 | — |
| Sep 3, 2026 | Keher (Nick) | Bought at price 2.19 per share. | 15.3K | $33.56K |
| Sep 3, 2026 | Novo Holdings A/S | — | 48.86M | — |
| Aug 31, 2026 | Novo Holdings A/S | — | 3.80M | — |
| Aug 19, 2026 | Parys (Francis Van) | — | 49.7K | — |
| Aug 11, 2026 | Parys (Francis Van) | Bought at price 1.75 per share. | 114 | $199 |
| Aug 11, 2026 | Parys (Francis Van) | — | 114 | — |
| Aug 11, 2026 | Keher (Nick) | Bought at price 1.75 per share. | 115 | $201 |
| Aug 11, 2026 | Keher (Nick) | — | 115 | — |
| Jul 12, 2026 | Keher (Nick) | Bought at price 1.62 per share. | 123 | $198 |
| Jul 12, 2026 | Keher (Nick) | — | 123 | — |
| Jul 12, 2026 | Parys (Francis Van) | Bought at price 1.62 per share. | 124 | $200 |
| Jul 12, 2026 | Parys (Francis Van) | — | 124 | — |
| Jun 10, 2026 | Parys (Francis Van) | Bought at price 1.66 per share. | 121 | $201 |
| Jun 10, 2026 | Parys (Francis Van) | — | 121 | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 20.7 | -14.1 | -16.8 | 1.4 | 27.4 | -13.3 | -8.6 | 55.3 | 23.6 | -4.1 | +62.5% | ||
| 2025 | 13.2 | -22.8 | -9.1 | 16.2 | 3.8 | 10.9 | 49.0 | -11.3 | -15.8 | -10.0 | 2.8 | -8.9 | −0.3% |
| 2024 | -23.0 | -17.0 | -8.6 | -19.1 | 9.1 | -12.0 | 28.0 | -2.9 | 35.6 | -15.5 | 18.3 | -19.0 | −38.1% |
| 2023 | -4.1 | -11.6 | 6.5 | 3.3 | 17.6 | -21.1 | 23.7 | -9.8 | -13.6 | -1.0 | -4.9 | 7.5 | −15.5% |
| 2022 | -30.5 | -5.3 | -13.4 | -23.0 | 5.1 | -14.1 | 15.2 | -14.0 | -6.4 | 2.3 | -2.5 | -3.7 | −64.7% |
| 2021 | -8.8 | 23.5 | 1.2 | +13.9% |
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
Buy / hold / sell counts
No recent headlines.